Radiation therapy equipment developer RefleXion announced that it will install its X1 radiation therapy system at the University of Pittsburgh Medical Center's Hillman Cancer Center.
X1 combines PET/CT with RefleXion's biology-guided radiotherapy, which directs treatment photons to sites of cancer detected with the PET/CT component, the company said. Treatments at UPMC should begin in the summer.
The X1 is currently approved for use in conventional stereotactic body radiotherapy, intensity-modulated radiation therapy, and stereotactic radiosurgery. The biology-guided radiotherapy feature is under investigational use until it receives official approval from the U.S. Food and Drug Administration.
In April 2020, RefleXion sold its first X1 system for installation at the Stanford Cancer Institute at Stanford University.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
